

Special Issue

Drugs of the Kallikrein-Kinin System

Message from the Guest Editor

The new MDPI journal *Drugs and Drug Candidates* is exploring the interest of the kinin community for a Special Issue under the title “Drugs of the Kallikrein-Kinin System”. Many recent and exciting therapeutic developments in the field justify this editorial project. Notably, various novel strategies are being developed to inhibit the formation of bradykinin or block its receptors in the management of hereditary angioedema. Several other applications are currently being investigated. Harnessing controlled kinin formation is also of potential therapeutic interest, as shown by the clinical development of recombinant tissue kallikrein for ischemic stroke and renal disease. Original research papers or review papers are welcome for submission to this Special Issue. Submissions will be rigorously peer-reviewed.

Guest Editor

Dr. François Marceau

Department of Microbiology, Infectious Disease and Immunology,
Faculty of Medicine, Université Laval, Québec, QC, Canada

Deadline for manuscript submissions

closed (31 August 2025)



Drugs and Drug Candidates

an Open Access Journal
by MDPI

Indexed in Scopus



mdpi.com/si/164630

Drugs and Drug Candidates
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ddc@mdpi.com

mdpi.com/journal/

[ddc](https://mdpi.com/journal/ddc)





Drugs and Drug Candidates

an Open Access Journal
by MDPI

Indexed in Scopus



[mdpi.com/journal/
ddc](https://doi.org/10.3390/journal/ddc)



About the Journal

Message from the Editor-in-Chief

Drugs and Drug Candidates is an open access initiative of MDPI (Basel, Switzerland). Do you wish to share your knowledge on marketed or newly approved drugs for human or veterinary use? Do you wish to disseminate your recent results on the search for novel promising drug candidates? Our journal, animated by a young and dynamic team, is the ideal platform! Your submission, carefully followed by an academic editor, will be peer-reviewed by experts in the field of the work and a first decision will be notified within no more than two weeks. Involved in drug design, drug synthesis, drug evaluation, or drug market, *Drugs and Drug Candidates* is of worthy recognition and value.

I look forward to handling your contributions in the very near future. Should you need any information, do not hesitate to contact us.

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde

Formerly Head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.8 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the second half of 2025).